Parallel Advisors, LLC Esperion Therapeutics, Inc. Transaction History
Parallel Advisors, LLC
- $4.87 Billion
- Q2 2025
A detailed history of Parallel Advisors, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 127,424 shares of ESPR stock, worth $344,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,424
Previous 10,000
1174.24%
Holding current value
$344,044
Previous $15,000
726.67%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ESPR
# of Institutions
181Shares Held
106MCall Options Held
139KPut Options Held
604K-
Black Rock Inc. New York, NY14MShares$37.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$31.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.3MShares$27.9 Million0.05% of portfolio
-
Two Seas Capital LP Rye, NY9.95MShares$26.9 Million0.18% of portfolio
-
Pender Fund Capital Management Ltd. Vancouver, A16.68MShares$18 Million4.26% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $180M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...